文献速递基础与转化研究新药、器械与细胞基因治疗研发

抗GD2 CAR T细胞对H3-K27M+弥漫性中线胶质瘤显示出强效抗肿瘤作用

Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas.
PubMed 文献 · Nat Med · 2018-04-16

该研究报道患者来源的H3-K27M突变胶质瘤细胞培养物均高表达GD2,含4-1BBz共刺激域的GD2靶向CAR T细胞在体外表现出抗原依赖性细胞因子生成和杀伤DMG细胞。在五个独立患者来源H3-K27M+ DMG原位异种移植模型中,全身给予GD2靶向CAR T细胞清除了移植肿瘤,仅残留少量GD2lo胶质瘤细胞。尽管多数小鼠耐受,但急性期瘤周神经炎症导致部分动物发生致死性脑积水,提示人体转化需密切监测和积极神经重症管理。

要点

  • 患者来源H3-K27M突变胶质瘤细胞培养物均高表达GD2,为CAR T靶点提供依据。
  • GD2靶向CAR T细胞在体外表现出抗原依赖性细胞因子生成和杀伤DMG细胞。
  • 五个原位异种移植模型中全身给药清除肿瘤,但残留少量GD2lo细胞且部分小鼠出现致死性脑积水。

核心结论

  • GD2靶向CAR T细胞在H3-K27M+ DMG临床前模型中显示强效抗肿瘤活性,但需警惕神经炎症相关毒性。

研究设计与样本

  • 研究采用患者来源H3-K27M突变胶质瘤细胞培养物及五个独立患者来源H3-K27M+ DMG原位异种移植模型进行临床前评估。

主要发现

  • 患者来源H3-K27M突变胶质瘤细胞培养物均高表达GD2。
  • 含4-1BBz共刺激域的GD2靶向CAR T细胞在体外表现出抗原依赖性细胞因子生成和杀伤DMG细胞。
  • 五个独立患者来源H3-K27M+ DMG原位异种移植模型中,全身给予GD2靶向CAR T细胞清除了移植肿瘤,仅残留少量GD2lo胶质瘤细胞。
  • GD2靶向CAR T细胞在多数原位异种移植小鼠中耐受,但急性期瘤周神经炎症导致部分动物发生致死性脑积水。

临床怎么用

  • 鉴于中线胶质瘤神经解剖位置险要,人体转化需密切监测并采取积极神经重症管理。
  • 需采用谨慎的多学科临床策略推进GD2靶向CAR T细胞治疗H3-K27M+脑桥、丘脑和脊髓弥漫性胶质瘤。

局限性

  • 临床前研究,人体安全性和有效性尚未确定。
  • 部分动物出现致死性脑积水,提示神经炎症毒性风险。
  • 肿瘤清除后残留少量GD2lo胶质瘤细胞。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs) with mutated histone H3 K27M (H3-K27M)1-5 are aggressive and universally fatal pediatric brain cancers 6 . Chimeric antigen receptor (CAR)-expressing T cells have mediated impressive clinical activity in B cell malignancies7-10, and recent results suggest benefit in central nervous system malignancies11-13. Here, we report that patient-derived H3-K27M-mutant glioma cell cultures exhibit uniform, high expression of the disialoganglioside GD2. Anti-GD2 CAR T cells incorporating a 4-1BBz costimulatory domain 14 demonstrated robust antigen-dependent cytokine generation and killing of DMG cells in vitro. In five independent patient-derived H3-K27M+ DMG orthotopic xenograft models, systemic administration of GD2-targeted CAR T cells cleared engrafted tumors except for a small number of residual GD2lo glioma cells. To date, GD2-targeted CAR T cells have been well tolerated in clinical trials15-17. Although GD2-targeted CAR T cell administration was tolerated in the majority of mice bearing orthotopic xenografts, peritumoral neuroinflammation during the acute phase of antitumor activity resulted in hydrocephalus that was lethal in a fraction of animals. Given the precarious neuroanatomical location of midline gliomas, careful monitoring and aggressive neurointensive care management will be required for human translation. With a cautious multidisciplinary clinical approach, GD2-targeted CAR T cell therapy for H3-K27M+ diffuse gliomas of pons, thalamus and spinal cord could prove transformative for these lethal childhood cancers.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Mount CW, Majzner RG, Sundaresh S, et al. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M+ diffuse midline gliomas. Nat Med. 2018. PMID: 29662203. doi:10.1038/s41591-018-0006-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。